Therefore, the findings suggest that the IL-33/ST2 pathway may delay the destruction of beta cells by regulating the immune response of the body, which suggests that the IL-33/ST2 pathway may be a promising therapeutic target for preventing T1D. This evidence concerns the gene IL33 and type 1 diabetes mellitus.